Lupin to invest $250m in new Florida manufacturing plant

Lupin announced plans today to build a new pharmaceutical manufacturing plant in Coral Springs, Florida, representing a significant expansion of its U.S. footprint. The company projects a cumulative investment of $250 million over five years, encompassing research and development, infrastructure, and capital expenditures. This facility is designed to produce over 25 critical respiratory medicines, including albuterol inhalers, enhancing domestic manufacturing and supply chain diversification.

The new state-of-the-art facility, spanning over 5 acres and 70,000 square feet, will create over 200 new long-term, skilled jobs in Broward County by 2030. It aims to anchor U.S. production of critical respiratory therapies, ensure affordable and reliable access, and serve pediatric to pandemic-scale demand. Lupin will receive tax credits and incentives from the state of Florida in recognition of its investment and job creation.

This expansion builds on Lupin's existing presence in Florida, which houses its U.S. headquarters and Advanced Inhalation Research Center. The project demonstrates Lupin's commitment to innovation, quality, and supply chain reliability, strengthening its position as a global respiratory leader.